# Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy

> **NCT06552572** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Glofitamab

## Key facts

- **NCT ID:** NCT06552572
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-26
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552572, "Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06552572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*